212 related articles for article (PubMed ID: 30908678)
1. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
2. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers.
Stickel F; Lutz P; Buch S; Nischalke HD; Silva I; Rausch V; Fischer J; Weiss KH; Gotthardt D; Rosendahl J; Marot A; Elamly M; Krawczyk M; Casper M; Lammert F; Buckley TWM; McQuillin A; Spengler U; Eyer F; Vogel A; Marhenke S; von Felden J; Wege H; Sharma R; Atkinson S; Franke A; Nehring S; Moser V; Schafmayer C; Spahr L; Lackner C; Stauber RE; Canbay A; Link A; Valenti L; Grove JI; Aithal GP; Marquardt JU; Fateen W; Zopf S; Dufour JF; Trebicka J; Datz C; Deltenre P; Mueller S; Berg T; Hampe J; Morgan MY
Hepatology; 2020 Jul; 72(1):88-102. PubMed ID: 31630428
[TBL] [Abstract][Full Text] [Related]
4. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
5. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
6. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
[TBL] [Abstract][Full Text] [Related]
7. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.
Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M
Liver Int; 2020 Feb; 40(2):393-404. PubMed ID: 31967400
[TBL] [Abstract][Full Text] [Related]
8. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
Pirola CJ; Garaycoechea M; Flichman D; Arrese M; San Martino J; Gazzi C; Castaño GO; Sookoian S
J Lipid Res; 2019 Jan; 60(1):176-185. PubMed ID: 30323112
[TBL] [Abstract][Full Text] [Related]
9. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population.
Chen H; Zhang Y; Guo T; Yang F; Mao Y; Li L; Liu C; Gao H; Jin Y; Che Y; Li Y; Huang J
Liver Int; 2020 Sep; 40(9):2194-2202. PubMed ID: 33151633
[TBL] [Abstract][Full Text] [Related]
10. A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.
Nischalke HD; Lutz P; Krämer B; Söhne J; Müller T; Rosendahl J; Fischer J; Berg T; Hittatiya K; Fischer HP; Soyka M; Semmo N; Nattermann J; Sauerbruch T; Strassburg CP; Stickel F; Spengler U
J Hepatol; 2014 Nov; 61(5):1073-9. PubMed ID: 24946282
[TBL] [Abstract][Full Text] [Related]
11. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
[TBL] [Abstract][Full Text] [Related]
12. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
13. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.
Kallwitz E; Tayo BO; Kuniholm MH; Daviglus M; Zeng D; Isasi CR; Cotler SJ
Liver Int; 2020 Apr; 40(4):889-893. PubMed ID: 31965669
[TBL] [Abstract][Full Text] [Related]
14. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma.
Innes H; Morgan MY; Hampe J; Stickel F; Buch S
Aliment Pharmacol Ther; 2023 Sep; 58(6):623-631. PubMed ID: 37470344
[TBL] [Abstract][Full Text] [Related]
15. The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.
Di Sessa A; Umano GR; Cirillo G; Marzuillo P; Arienzo MR; Pedullà M; Miraglia Del Giudice E
J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):371-374. PubMed ID: 31789772
[TBL] [Abstract][Full Text] [Related]
16. Interplay of
De Benedittis C; Bellan M; Crevola M; Boin E; Barbaglia MN; Mallela VR; Ravanini P; Ceriani E; Fangazio S; Sainaghi PP; Burlone ME; Minisini R; Pirisi M
Gastroenterol Res Pract; 2020; 2020():4216451. PubMed ID: 32382265
[TBL] [Abstract][Full Text] [Related]
17. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma.
Chen J; Zhuo JY; Yang F; Liu ZK; Zhou L; Xie HY; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):220-226. PubMed ID: 29748147
[TBL] [Abstract][Full Text] [Related]
18. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
Gellert-Kristensen H; Richardson TG; Davey Smith G; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Sep; 72(3):845-856. PubMed ID: 32190914
[TBL] [Abstract][Full Text] [Related]
19. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
20. Impact of a Loss-of-Function Variant in
Gil-Gómez A; Rojas Á; García-Lozano MR; Muñoz-Hernández R; Gallego-Durán R; Maya-Miles D; Montero-Vallejo R; Gato S; Gallego J; Francés R; Soriano G; Ampuero J; Romero-Gómez M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]